VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Balar on Combinations with Pembrolizumab for Urothelial Cancer

Arjun V. Balar, MD
Published: Friday, Jul 21, 2017



Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are several combination strategies that are noteworthy for pembrolizumab, explains Balar. There is a combination of pembrolizumab, radiation, and chemotherapy in patients with localized muscle invasive bladder cancer, which is currently being investigated.

Additionally, there is a randomized phase III trial of pembrolizumab with epacadostat versus single-agent pembrolizumab which many are excited to see the results of, states Balar.



Arjun V. Balar, MD, assistant professor of Medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

There are several combination strategies that are noteworthy for pembrolizumab, explains Balar. There is a combination of pembrolizumab, radiation, and chemotherapy in patients with localized muscle invasive bladder cancer, which is currently being investigated.

Additionally, there is a randomized phase III trial of pembrolizumab with epacadostat versus single-agent pembrolizumab which many are excited to see the results of, states Balar.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x